1. Introduction {#sec1-jcm-07-00285}
===============

The burden of chronic kidney disease (CKD) is estimated to affect 26 million people in the USA and continues to increase globally \[[@B1-jcm-07-00285]\]. A significant amount of CKD and end-stage renal disease (ESRD) patients on dialysis succumb to accelerated cardiovascular disease (CVD) \[[@B2-jcm-07-00285]\]. Meta-analyses and observational studies have disclosed a 1.4--3.7-fold increase in mortality from CVD among patients with CKD compared to those without CKD \[[@B2-jcm-07-00285]\].

Recently, meta-analysis studies have shown that statin (3-hydroxy-3-methylglutaryl coenzyme A \[HMG-CoA\]) reductase inhibitors therapy prevents major adverse cardiovascular events (MACE) in patients with CKD stages I-IV \[[@B3-jcm-07-00285]\], but there was little or no benefit for MACE prevention in patients undergoing dialysis \[[@B4-jcm-07-00285],[@B5-jcm-07-00285]\]. As such, according to the Kidney Disease Improving Global Outcomes (KDIGO) CKD guideline, dialysis-dependent patients should not initiate statin therapy \[[@B6-jcm-07-00285]\]. However, whether or not the use of statins is effective against MACE and all-cause mortality among advanced CKD (pre-dialysis patients, estimated glomerular filtration rate \<15 mL/min/1.73 m^2^) patients is still unknown. The the long-term use of statins is associated with an increase in hyperglycemia and overt diabetes mellitus \[[@B7-jcm-07-00285]\]; additionally, studies that have assessed the benefits of statins have not extensively discussed the risk of new-onset diabetes mellitus (NODM) for patients with advanced CKD \[[@B8-jcm-07-00285]\]. Furthermore, exposure to statins may have a protective effect against the development of sepsis and decrease mortality in critically ill patients \[[@B9-jcm-07-00285]\], and yet such results have not been concluded in advanced CKD patients.

Thus, we aimed to evaluate the effects of statin use on NODM, de novo MACE, or all-cause mortality including cardiovascular-related deaths and severe sepsis-related deaths among advanced CKD population in a nationwide cohort.

2. Materials and Methods {#sec2-jcm-07-00285}
========================

2.1. Data Source {#sec2dot1-jcm-07-00285}
----------------

This population-based cohort study retrieved data from the Taiwan National Health Insurance (TNHI) Research Database, which is one of the largest health insurance databases in the world and has been used extensively in various epidemiologic studies \[[@B10-jcm-07-00285],[@B11-jcm-07-00285]\]. The TNHI covers almost all 23.7 million people in Taiwan and contains comprehensive healthcare information regarding outpatient visits, hospital admissions, disease profiles, prescriptions, interventional procedures, and vital status. All diagnoses are based on the codes of the International Classification of Diseases, 9th Revision (ICD-9).

2.2. Study Population {#sec2dot2-jcm-07-00285}
---------------------

This study retrospectively enrolled patients aged ≥20 years who had diagnosis codes for CKD and were treated with erythropoiesis-stimulating agents (ESAs) from 1 January 2000 to 31 December 2010. According to the TNHI reimbursement policy, ESAs can only be prescribed in predialysis CKD patients with anemia who have a hematocrit level of ≤28% and a serum creatinine level of \> 6 mg/dL (equivalent to an estimated glomerular filtration rate (eGFR) of \<15 mL/min/1.73 m^2^, CKD stage 5) with a goal of maintaining a hematocrit level of 33%--36%. We defined this combination of CKD diagnosis codes and predialysis patients using ESAs as 'advanced CKD'. We only included advanced CKD patients who were new users of statins after the first prescription of ESAs. Patients who had been treated with dialysis (identified by procedure codes) or underwent renal transplantation before ESA prescription and those who did not survive 90 days after the first ESA therapy were excluded ([Figure 1](#jcm-07-00285-f001){ref-type="fig"}).

Patients with NODM (no pre-existing diabetes mellitus at enrollment) during the follow-up period were identified. To observe the effect of statins on the prevention of cardiovascular events in these advanced CKD patients, we also excluded patients who had MACE recorded before advanced CKD enrollment. As such, this also prevented ICD codes of prior MACE to carry over, in order to avoid misclassification bias. Each drug dispensing is registered based on international classification of drugs, the Anatomical Therapeutic Chemical (ATC) system, as well as the date of dispensing, quantity dispensed, strength, and formulation. The baseline comorbidities, including diabetes and CKD, were identified from at least one in-patient claim or three ambulatory visits within one year preceding the first ESA treatment. This identification approach has been validated with good predictive power \[[@B10-jcm-07-00285],[@B11-jcm-07-00285],[@B12-jcm-07-00285]\]. The Charlson comorbidity index was also calculated by weighing baseline comorbidities \[[@B13-jcm-07-00285]\].

2.3. Outcome Measures {#sec2dot3-jcm-07-00285}
---------------------

The primary outcome was all-cause mortality, MACE-related or severe sepsis-related deaths. Sepsis was defined according to the American College of Chest Physicians/Society of Critical Care Medicine (ACCP/SCCM) as a systemic inflammatory syndrome in response to infection, which when associated with acute organ dysfunction is said to be severe \[[@B14-jcm-07-00285]\] (Supplementary methods). The secondary outcome was NODM and de novo MACE after statin use. NODM was defined vianew prescriptions for any anti-diabetic drugs (oral agents or insulin) together with the ICD code of diabetes while the outcome of diabetes was defined by any prescriptions for diabetes drugs (oral agents or insulin) in consecutive visits (\>30 days apart) \[[@B15-jcm-07-00285],[@B16-jcm-07-00285],[@B17-jcm-07-00285]\]. De novo MACE included non-fatal myocardial infarction (MI), coronary artery bypass graft (CABG), stroke and coronary angiography \[[@B18-jcm-07-00285]\]. All patients were followed from the date of the first ESA prescription to the date of the first occurrence of the outcome event, and censored at either death, transplantation or the end of the study (31 December 2011), whichever occurred first.

2.4. Exposure Assessment {#sec2dot4-jcm-07-00285}
------------------------

We identified statin treatment in accordance with the prescription for statins during the study period, and restricted our analysis to new users by requiring a period of at least one year without any prescription for statins before the diagnosis of advanced CKD. The statin users and non-users were matched at a 1:3 ratio by propensity scoring, in an attempt to make an unbiased estimate of all the baseline confounders ([Figure 1](#jcm-07-00285-f001){ref-type="fig"}). The doses of statin were converted to the number of defined daily doses (DDDs) as defined by the World Health Organization \[[@B19-jcm-07-00285]\] using the time-span of 60 days preceding outcomes. A DDD is equal to atorvastatin 20 mg (supplementary methods).

2.5. Ethics Committee Approval {#sec2dot5-jcm-07-00285}
------------------------------

As all personal information is de-identified in the TNHI Research Database, informed consent was waived and this study was exempt from a full ethical review by the institutional review board of the National Taiwan University Hospital (201212021RINC).

2.6. Statistical Analysis {#sec2dot6-jcm-07-00285}
-------------------------

Continuous variables were presented as the mean ± standard deviation (SD) or median, as appropriate. We performed a propensity score matching (PSM) to reduce the selection bias due to the baseline differences between the statin users and non-users. First, we conducted multivariable logistic regression analysis to identify the predictors for the prescription of statin. Baseline comorbid conditions, age, and sex (listed in [Table 1](#jcm-07-00285-t001){ref-type="table"}) were inputted into a non-parsimonious multivariable logistic regression model to predict the prescription of statin. The predicted probability derived from the estimated equation was the propensity score for each individual ([Table S1](#app1-jcm-07-00285){ref-type="app"}). Then, we used the "Match ()" function in the "Matching" library of the R statistical software to do PSM based on the default value of "caliper" (i.e., caliper = 0.25) and the Mahalanobis distance without replacement. After the matching, the standardized mean difference (SMD) of all variables were \<0.1 ([Table 1](#jcm-07-00285-t001){ref-type="table"}).

We evaluated the risk factors of outcomes and death using Cox proportional hazards models with all statins and ESRD as time-dependent covariates to account for their impact. Time-dependent analytical methods have been shown to avoid time bias in observational cohort studies \[[@B18-jcm-07-00285]\]. Variable selection for Cox regression hazards modeling was performed using step-wise multiple regression, with a *p*-to-enter and *p*-to-leave both equal to 0.15. The validity of the proportional hazard assumption, linearity of continuous variables, and lack of interaction were found to be valid unless otherwise indicated. Because of the higher mortality rate and metabolic disease in CKD patients, competing-risk regression using the Fine and Gray model by considering the subdistribution hazard was also performed.

After adjustment for comorbidities, we also conducted an adjusted comparison of risks for statin-associated NODM or mortality among patient subgroups stratified by the status of comorbidities, subsequent ESRD, and category of statins, as shown in the forest plot.

To evaluate the effect of statin dose on the risk of all-cause mortality, we further adopted a generalized additive model (GAM) with adjustments for baseline comorbidities and the risk of mortality. This method grants adjustments for possible non-linear effects from continuous variables \[[@B6-jcm-07-00285]\]. The result was shown as a function curve with values of the log odds ratio and was centered to have an average of zero over the range of the data.

All analyses were carried out using R software, version 3.1.2 (Free Software Foundation, Inc., Boston, MA, USA). A two-sided *p*-value \< 0.05 was considered significant.

3. Results {#sec3-jcm-07-00285}
==========

3.1. Patient Characteristics {#sec3dot1-jcm-07-00285}
----------------------------

Among advanced CKD patients before PSM, statin users (*n* = 3090) were more frequently females, younger, and had lower rates of comorbidities (except hypertension) than statin non-users (*n* = 11,362). After PSM (1:3 ratio, [Figure 1](#jcm-07-00285-f001){ref-type="fig"}), 2551 statin users were compared with 7653 statin non-users as controls. The average ages, gender distributions and Charlson comorbidity indeices were not significantly different, and the proportions of comorbidities, antihypertensive drugs, and major medication uses were similar between the two groups ([Table 1](#jcm-07-00285-t001){ref-type="table"}).

3.2. Effect of Statins on NODM {#sec3dot2-jcm-07-00285}
------------------------------

After a mean follow-up of 5.3 ± 3.1 years, the unadjusted rate of NODM was not significantly different between statin users and non-users. For multivariate time-dependent Cox regression analysis, the use of statin increased the risk of NODM before (HR = 1.45, 95% CI, 1.16--1.82, *p* = 0.001) and after PSM (HR = 1.46, 95% CI, 1.14--1.85, *p* = 0.002) compared to statin non-users. However, when taking the competing risk for mortality into account for the time-dependent model analysis, statin use did not augment the risk of NODM before or after PSM ([Table 2](#jcm-07-00285-t002){ref-type="table"}).

3.3. Effect of Statins on De Novo MACE {#sec3dot3-jcm-07-00285}
--------------------------------------

For de novo MACE, statin usage was not protective in comparison to non-users in univariate analysis. Furthermore, statin users among advanced CKD patients did not have a reduced risk of de novo MACE both in the adjusted and competing risk models ([Table 2](#jcm-07-00285-t002){ref-type="table"}). In regard to de novo MACE, advanced CKD patients either with (HR = 1.21, 95% CI, 0.8--1.84, *p* = 0.645) or without (HR = 1.25, 95% CI, 0.7--1.95, *p* = 0.701) subsequent dialysis also could not benefit from statin treatment.

3.4. Effect of Statins on Mortality {#sec3dot4-jcm-07-00285}
-----------------------------------

After PSM, the risk of all-cause mortality was improved following statin use among advanced CKD patients (HR = 0.59, 95% CI, 0.42--0.84, *p* = 0.004). On identifying the etiologies attributed to mortality, statin users had reduced odds of sepsis-related mortality (HR = 0.53, 95% CI, 0.32--0.87, *p* = 0.012), although MACE-related mortality was not significantly reduced (HR = 1.75, 95% CI, 0.87--3.13, *p* = 0.065) ([Table 2](#jcm-07-00285-t002){ref-type="table"}).

From the forest plot, statin use decreased all-cause mortality in subgroups of different baseline characteristics and comorbidities consistently after PSM ([Figure 2](#jcm-07-00285-f002){ref-type="fig"}). This protective effect was significant among patients who subsequently developed a dialysis-dependent status as well as those who were pre-dialysis advanced CKD patients.

We further assessed the risk of all-cause mortality for the class effect of various statins by forest plot analysis after PSM, and found that all statins reduced mortality for advanced CKD patients ([Figure 3](#jcm-07-00285-f003){ref-type="fig"}).

Additionally, we evaluated the cumulative doses between DDD before the event and the risk of all-cause mortality utilizing a GAM analysis. The function curve was nonlinear and there was a significant trend approaching decreased all-cause mortality, especially for a daily statin dose \>0.122 DDD (equal to 2.4 mg atorvastatin) within a time-span of 60 days, before leveling out after approximately 1.0 DDD ([Figure 4](#jcm-07-00285-f004){ref-type="fig"}).

4. Discussion {#sec4-jcm-07-00285}
=============

Our study supports the clinical benefit of statin therapy among advanced CKD patients in the reduction of all-cause mortality and especially sepsis-related mortality. In addition, after the competing risk for mortality taken into account, statin therapy was not associated with an increased risk of NODM, nor was it associated with a decreased incidence of de novo MACE.

Although statin use is associated with lower incidence of CVD in the general population or even in patients with mild to moderate CKD \[[@B2-jcm-07-00285],[@B3-jcm-07-00285],[@B20-jcm-07-00285],[@B21-jcm-07-00285]\], our study demonstrated that the primary prevention by statins of lowering the CVD/MACE risk among advanced CKD patients was not prominent in this analysis of a large "real-world" contemporary population-based cohort. To our knowledge, we are the first to identify the effect of new statin therapy in alleviating all-cause mortality, mainly from sepsis-related deaths for advanced CKD patients. We also present the incidence of de novo MACE and NODM after statin use in this population.

4.1. Statin Decreased Sepsis and Mortality {#sec4dot1-jcm-07-00285}
------------------------------------------

In this study, we found that statin treatment in advanced CKD patients, even those progressing to ESRD, was associated with a reduced risk of all-cause mortality, mainly from sepsis-related deaths. Statin therapy could aid the treatment and prevention of sepsis by targeting a number of inflammatory and immune-modulating cascades involved in sepsis \[[@B22-jcm-07-00285]\]. Additionally, statins were strongly and independently associated with a reduction in the risk of sepsis events in patients who had chronic kidney disease \[[@B23-jcm-07-00285]\]. Furthermore, statins have demonstrated the ability to reduce a number of pro-inflammatory cytokines known to be detrimental in the development and progression of sepsis and limit the coagulation response, promoting fibrinolysis in the setting of sepsis \[[@B24-jcm-07-00285]\]. Given the current uncertainty in the medical literature about the benefits of lowering lipid levels in advanced CKD patients for reducing the incidence of mortality, our findings are timely and reassuring. We further reinforce the notion that statin treatment in a very high-risk advanced CKD population could be beneficial in reducing sepsis-related mortality. The anti-inflammatory effects of statins are associated with higher dose regents \[[@B25-jcm-07-00285]\]; likewise, from DDD analysis in our CKD patients, the survival benefits of statins also seemed to be dose-dependent, and the reduction in risk was constant after a 1.0 DDD. Our findings may shed light on some heterogeneity of findings in previous similar studies, as all statins in this class showed a consistent protective effect against all-cause mortality.

4.2. NODM after Statin Treatment {#sec4dot2-jcm-07-00285}
--------------------------------

While statin therapy in mild CKD patients could induce a dose-dependent risk of NODM, no such risk was evident among advanced CKD patients. Although the underlying mechanisms for the association between insulin resistance and CKD remain unclear, numerous mechanisms such as glucose dysregulation, uremic toxin retention, inflammation, abnormal mineral metabolism, hypertension, adiposity, and uremic acidosis have been implicated \[[@B26-jcm-07-00285]\]. Potential contributors to this so-called "burnt-out diabetes" include decreased renal and hepatic insulin clearance, a decline in renal gluconeogenesis, deficient catecholamine release, diminished food intake (because of anorexia or diabetic gastroparesis) and protein-energy wasting (with resultant loss of weight and body fat) \[[@B27-jcm-07-00285]\]. All the factors delineate to less hyperglycemia in advanced CKD patients.

4.3. De Novo MACE after Statin Treatment {#sec4dot3-jcm-07-00285}
----------------------------------------

Several reviews of statin therapy have generally concluded that lipid-lowering is beneficial in early-stage CKD, but results in ESRD differ \[[@B5-jcm-07-00285],[@B28-jcm-07-00285],[@B29-jcm-07-00285]\]. Randomized studies have indicated that statins have a limited role in the primary prevention of CVD or mortality in patients undergoing dialysis \[[@B6-jcm-07-00285]\]. Our study revealed that among patients with advanced CKD, there was a benefit of decreased all-cause mortality after statin use; however, the benefit on CVD prevention was limited.

Although several different medications could lower LDL-C, only regimens including statins have been convincingly shown to reduce the risk of adverse cardiovascular events in mild to moderate CKD populations \[[@B2-jcm-07-00285]\]. However, similar observations were not found in our patients with advanced CKD. The most likely explanation of the findings from the aforementioned trials is that arterial lesions in advanced CKD patients (which also have different pathogenesis to arterial lesions in patients without CKD or mild CKD \[[@B30-jcm-07-00285]\]) are so severe that they are unlikely to be meaningfully reduced by statins. Another possibility could be the short duration of statin treatment among our advanced CKD enrollees before their subsequent dialysis.

4.4. Strength and Limitations {#sec4dot4-jcm-07-00285}
-----------------------------

There were limitations in the present study. First, personal information that might affect the risk of NODM, including glucose levels, smoking and alcohol habits, physical activity and body mass index, were unavailable from the TNHI Research Database. Some uncorrected confounders were not available in the database, which might potentially influence the outcome. Second, we only studied patients without pre-existing diabetes to observe the long-term effect of statins on NODM, CVD and all-cause mortality, suggesting that treatment with statins in the primary prevention of CVD, including for diabetic patients, should be investigated further. Third, our target population of patients with advanced CKD was identified by ICD-9 codes for CKD plus drug codes for ESA \[[@B31-jcm-07-00285]\]. Given that the rate of ESA prescription was 85% in 2012 in predialysis stage 5 CKD patients according to an internal report of the Taiwan Department of Health, we believe that the patients on ESA therapy were representative and constituted the majority of stage 5 CKD patients. Fourth, since the nutritional status affects infection and mortality, we do not have the data of body mass index and serum albumin level.

Finally, the use of statins was not randomly assigned, and the factors attributed to their prescription could not be adequately assessed and accounted. However, because the NHI database contains prescription information, we were able to determine how often prescriptions were refilled as a marker of whether statins were being taken as prescribed. With PSM, patients were matched on a single propensity score representing the probability of receiving the exposure of interest given the observed baseline characteristics; this method is especially useful when treatment cohorts are dissimilar.

In this study, we used the large-scale population-based cohort database, which offered insights into the effects of statin use among advanced CKD patients that were not examined and could not be offered via the smaller-scale multicenter studies. Further randomized prospective studies are needed to confirm our results.

5. Conclusions {#sec5-jcm-07-00285}
==============

In conclusion, this large population-based cohort study provides evidence for decreased mortality among advanced CKD patients initiating statin treatment. Our analysis showed that statin use did not significantly increase the risk of NODM, nor was statin associated with decreased risk of de novo MACE among advanced CKD patients, when taking mortality into competing account. Statin could reduce the risk of all-cause mortality, mainly sepsis-related deaths. All of these findings need to be validated further with larger prospective studies focusing on advanced CKD patients.

The study was partly based on data provided by National Health Insurance Administration, Ministry of Health and Welfare, Taiwan. The interpretation and conclusions shown in this paper do not represent those of National Health Insurance Administration, Ministry of Health and Welfare, National Health Research Institutes, or National Taiwan University Hospital. We also express our sincere gratitude to all staff of the Taiwan Clinical Trial Consortium, TCTC. Conflict of interest statements: No completing interest was declared. No financial conflict of interest exists.

The following are available online at <http://www.mdpi.com/2077-0383/7/9/285/s1>, Table S1: Propensity score model in the probability of statin prescription, Supplementary methods: Outcome measures, Identification of individual statins.
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![Detailed flowchart for patient enrollment. Abbreviations: CKD, chronic kidney disease; ESA, erythropoiesis-stimulating agents; MACE, major adverse cardiac events.](jcm-07-00285-g001){#jcm-07-00285-f001}

![The adjusted hazard ratio for statin use versus nonuse in advanced chronic kidney disease patients on the incidence of all-cause mortality after propensity score matching, stratified by comorbidities. (ESRD, end-stage renal disease denoted who received subsequent chronic dialysis). Abbreviations: HR, harzard ratio; ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; CCB, calcium-channel blocker.](jcm-07-00285-g002){#jcm-07-00285-f002}

![The adjusted hazard ratio for statin users versus non-users in advanced chronic kidney disease patients on the incidence of all-cause mortality with post-propensity score matching, stratified according to individual statin therapy. HR, harzard ratio.](jcm-07-00285-g003){#jcm-07-00285-f003}

![The dose-response relationship between statins and the logit probability of all-cause mortality using generalized additive modeling (GAM). The adjustments for factors are listed in [Table 1](#jcm-07-00285-t001){ref-type="table"}. The dotted line indicates 95% confidence intervals.](jcm-07-00285-g004){#jcm-07-00285-f004}

jcm-07-00285-t001_Table 1

###### 

Clinical characteristics of statin users and non-users before and after propensity score match.

                                     Before PSM      After PSM                                                      
  ---------------------------------- --------------- --------------- -------------- --------------- --------------- --------
  Age                                57.61 ± 13.47   63.89 ± 15.06   0.439          59.41 ± 13.2    59.73 ± 14.99   0.023
  **Gender**, *n* (%)                                                                                               
  Women                              2109 (68.25%)   5984 (52.67%)   −0.323         1627 (63.78%)   4937 (64.51%)   0.015
  Men                                981 (31.75%)    5378 (47.33%)   924 (36.22%)   2716 (35.49%)                   
  Comorbidity                                                                                                       
  Charlson score                     1.99 ± 1.12     2.15 ± 1.28     0.136          2 ± 1.15        2.02 ± 1.14     0.020
  Congestive heart failure           149 (4.82%)     737 (6.49%)     −0.072         135 (5.29%)     412 (5.38%)     −0.004
  Peripheral vascular disease        12 (0.39%)      82 (0.72%)      −0.045         11 (0.43%)      47 (0.61%)      −0.025
  Dementia                           8 (0.26%)       115 (1.01%)     −0.095         8 (0.31%)       20 (0.26%)      0.010
  COPD                               188 (6.08%)     889 (7.82%)     −0.068         177 (6.94%)     465 (6.08%)     0.035
  Rheumatologic disease              81 (2.62%)      233 (2.05%)     0.038          53 (2.08%)      200 (2.61%)     −0.035
  Peptic Ulcer                       359 (11.62%)    1696 (14.93%)   −0.098         307 (12.03%)    928 (12.13%)    −0.003
  Hemiplegia                         2 (0.06%)       9 (0.08%)       −0.005         2 (0.08%)       6 (0.08%)       0.000
  Moderate or Severe liver disease   99 (3.20%)      685 (6.03%)     −0.135         95 (3.72%)      290 (3.79%)     −0.003
  Tumor                              115 (3.72%)     701 (6.17%)     −0.113         108 (4.23%)     320 (4.18%)     0.003
  Hypertension                       1935 (62.62%)   6868 (60.45%)   0.045          1574 (61.70%)   4726 (61.75%)   −0.001
  Gout                               479 (15.50%)    1967 (17.31%)   −0.049         409 (16.03%)    1181 (15.43%)   0.017
  Medication for hypertension                                                                                       
  Alpha-Blocker                      298 (9.64%)     1238 (10.90%)   −0.041         248 (9.72%)     696 (9.09%)     0.021
  Beta-Blocker                       1169 (37.83%)   3905 (34.37%)   0.072          931 (36.50%)    2786 (36.40%)   0.002
  Calcium-Channel Blocker            1765 (57.12%)   6373 (56.09%)   0.021          1462 (57.31%)   4261 (55.68%)   0.013
  Diuretic                           1076 (34.82%)   4740 (41.72%)   −0.142         933 (36.57%)    2801 (36.60%)   −0.001
  ACEI or ARB                        1332 (43.11%)   4468 (39.32%)   0.077          1059 (41.51%)   3181 (41.57%)   −0.001
  Other concomitant medication                                                                                      
  Aspirin                            99 (3.20%)      381 (3.35%)     −0.008         86 (3.37%)      229 (2.99%)     0.022
  Clopidogrel                        34 (1.10%)      139 (1.22%)     −0.011         32 (1.25%)      60 (0.78%)      0.027
  Ticlopidine                        26 (0.84%)      70 (0.62%)      0.026          13 (0.51%)      48 (0.63%)      −0.016
  Dipyridamole                       985 (31.88%)    3289 (28.95%)   0.064          788 (30.89%)    2368 (30.94%)   −0.001
  Nitrate                            8 (0.26%)       63 (0.55%)      −0.046         8 (0.31%)       35 (0.46%)      −0.023
  H2 blocker                         383 (12.39%)    1608 (14.15%)   −0.052         329 (12.90%)    969(12.66%)     0.007
  PPI                                171 (5.53%)     1054 (9.28%)    −0.143         160 (6.27%)     466 (6.09%)     0.008
  Pentoxifylline                     376 (12.17%)    1386 (12.20%)   −0.001         297 (11.64%)    932 (12.18%)    −0.017
  Sodium bicarbonate                 17 (0.55%)      43 (0.38%)      0.025          14 (0.55%)      29 (0.38%)      0.025

Values are mean ± SD or *n* (%). Abbreviations: ACEI, angiotensin-converting-enzyme inhibitors; ARB, Angiotensin II receptor blockers; COPD, chronic obstructive pulmonary disease; H2 blocker, Histamine 2 blockers; PSM, propensity score match; SD, standard deviation; SMD, standardized mean difference; PPI, proton-pump inhibitor.

jcm-07-00285-t002_Table 2

###### 

Risks for NODM, de novo MACE, all-cause mortality, MACE- and sepsis-related death before and after propensity score match.

                                      Statin Nonusers                     Statin Users          Crude                Adjusted \*   Competing \*\*                                     
  ---------------------- ------------ --------------------- ------ ------ -------------- ------ -------------------- ------------- -------------------- ------- --------------------- -------
                         before PSM   users vs. non-users                                                                                                                             
  NODM                   901          17,186.0              52.4   2660   46,591.5       57.1   1.21 \[0.95,1.54\]   0.130         1.45 \[1.16,1.82\]   0.001   1.16 \[0.95,1.41\]    0.152
  *De novo* MACE         939          17,069.7              55.0   2307   46,052.7       50.1   0.94 \[0.72,1.23\]   0.658         1.21 \[0.94,1.54\]   0.137   1.11 \[0.91, 1.36\]   0.323
  Mortality                                                                                                                                                                           
  All-cause mortality    586          20,168.9              29.1   3772   52,220.1       72.2   0.30 \[0.21,0.43\]   \<0.001       0.59 \[0.42,0.82\]   0.002   NA                    NA
  MACE-related death     64           20,168.9              3.2    224    52,220.1       4.3    1.77 \[0.98,3.19\]   0.059         1.84 \[0.82,3.31\]   0.073   NA                    NA
  Sepsis-related death   361          20,168.9              17.9   1964   52,220.1       37.6   0.29 \[0.18,0.47\]   \<0.001       0.58 \[0.37,0.91\]   0.017   NA                    NA
                         after PSM    users vs. non-users                                                                                                                             
  NODM                   773          13,851.4              55.8   1654   34,125.3       48.5   1.42 \[1.11,1.81\]   0.005         1.46 \[1.14,1.85\]   0.002   1.16 \[0.94,1.45\]    0.170
  *De novo* MACE         829          13,661.1              60.7   1459   33,983.3       42.9   1.16 \[0.89,1.51\]   0.265         1.23 \[0.95,1.59\]   0.124   1.14 \[0.93,1.4\]     0.220
  Mortality                                                                                                                                                                           
  All-cause mortality    526          16,370.3              32.1   2087   38,072.3       54.8   0.55 \[0.39,0.79\]   0.001         0.59 \[0.42,0.84\]   0.004   NA                    NA
  MACE-related death     56           16,370.3              3.4    130    38,072.3       3.4    1.38 \[0.71,2.66\]   0.339         1.75 \[0.87,3.13\]   0.065   NA                    NA
  Sepsis-related death   321          16,370.3              19.6   1071   38,072.3       28.1   0.49 \[0.3,0.81\]    0.005         0.53 \[0.32,0.87\]   0.012   NA                    NA

\* step-wise all variables in [Table 1](#jcm-07-00285-t001){ref-type="table"}, statin as time-varying risks. \*\* adjusted with age, sex, propensity score, taking mortality as the competing risk. Abbreviations: CI, confidence interval; HR, hazard ratio; sHR, subdistribution hazard ratio;IR, incidence rate (per 1000 person-years); MACE, major adverse cardiac events; NA, not applicable; NODM, new onset diabetes mellitus; PSM, propensity score match.
